Related Experiment Videos
Is platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer?
J P Roovers1, E A Sijmons, J H van Leeuwen
1Department of Obstetrics and Gynecology, University Medical Center, Utrecht, The Netherlands. j.p.roovers@azu.nl
Objective:
Suboptimally debulked patients with advanced ovarian cancer who are treated with a combination of cisplatin plus paclitaxel (TP therapy) have a better survival as compared to patients treated with a combination of cisplatin plus cyclophosphamide (CP therapy), but this advantage has not been demonstrated in optimally debulked patients. We performed a retrospective study to compare the effectiveness of TP therapy and CP therapy in optimally debulked patients.
Study Design:
From 1991 to 1996, 87 consecutive patients with advanced ovarian cancer treated in the University Hospital Utrecht and the St. Antonius Hospital were included in the study. Overall survival (OS) of patients treated with TP or CP were compared. Multivariable Cox-regression analysis was used to calculate a hazard rate ratio (HRR) for OS.
Results:
In the study period, 51 patients were treated with CP, and 36 patients were treated with TP. In the 18 patients with a tumorrest >2cm, there was a clear, but not statistically significant benefit from TP. In 69 patients with a tumorrest
Conclusion:
We could not show that ovarian cancer patients with residual disease of